Smital Shah
Director/Board Member bij PLIANT THERAPEUTICS, INC.
Vermogen: 18 757 $ op 31-03-2024
Profiel
Smital Shah is an Independent Director at Pliant Therapeutics, Inc. She previously served as an Independent Director at Graphite Bio, Inc. and as Treasurer at Gilead Sciences, Inc. from 2012 to 2014.
From 2018 to 2022, she held the position of Chief Financial & Business Officer at ProQR Therapeutics NV.
Ms. Shah holds an MBA from the University of California, Berkeley and the Haas School of Business.
She also has a graduate degree from Virginia Polytechnic Institute & State University and an undergraduate degree from the University of Mumbai.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0.00% | 01-02-2024 | 840 ( 0.00% ) | 18 757 $ | 31-03-2024 |
| 07-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Smital Shah
| Bedrijven | Functie | Begin |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 14-03-2019 |
Eerdere bekende functies van Smital Shah
| Bedrijven | Functie | Einde |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Director of Finance/CFO | 01-10-2022 |
| GILEAD SCIENCES, INC. | Treasurer | 01-09-2014 |
| LENZ THERAPEUTICS, INC. | Director/Board Member | - |
Opleiding van Smital Shah
| Virginia Polytechnic Institute & State University | Graduate Degree |
| University of Mumbai | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
